Compare Agilent Technologies Inc (A) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Vertex Pharmaceuticals Incorporated trades at $499.3 (market cap $132.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.6× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| A | VRTX | |
|---|---|---|
Market Cap | $37.04B | $132.55B |
Sector | Health | Health |
52-Week High | $157.20 | $529.59 |
52-Week Low | $110.24 | $366.54 |
Enterprise Value | $38.59B | $127.29B |
Dividend Yield | 0.78% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
